Zentalis Pharmaceuticals

(NASDAQ) ZNTL

Current Price$3.98

Market Cap$284.43M

Since IPO (2020)-83%

5 Year-93%

1 Year+182%

1 Month+71%

Zentalis Pharmaceuticals Financials at a Glance

Market Cap

$284.43M

Revenue (TTM)

$0.00

Net Income (TTM)

$137.06M

EPS (TTM)

$-1.91

P/E Ratio

-2.10

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$3.98

Volume

24,325

Open

$4.10

Price

$3.98

Volume

24,325

Open

$4.10

Previous Close

$3.98

Daily Range

$3.89 - $4.15

52-Week Range

$1.13 - $6.95

Dividend

$0.00

Beta (Volatility)

1.75 (High)

Price

$3.98

Volume

24,325

Open

$4.10

Previous Close

$3.98

Daily Range

$3.89 - $4.15

52-Week Range

$1.13 - $6.95

ZNTL News

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

David HaenApr 23, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zentalis Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

106

CEO

Julia Marie Eastland, MBA

Website

www.zentalis.com

Headquarters

New York City, NY 10018, US

ZNTL Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-50%

Return on Capital

-61%

Return on Assets

-47%

Earnings Yield

-47.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$284.43M

Shares Outstanding

70.93M

Volume

24.32K

Avg. Volume

1.91M

Financials (TTM)

Gross Profit

$739.00K

Operating Income

$146.25M

EBITDA

$145.51M

Operating Cash Flow

$125.25M

Capital Expenditure

$0.00

Free Cash Flow

$125.25M

Cash & ST Invst.

$245.89M

Total Debt

$39.58M

Zentalis Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$157.00K

-100.6%

Gross Margin

0.00%

N/A

Market Cap

$284.43M

N/A

Market Cap/Employee

$1.71M

N/A

Employees

166

N/A

Net Income

$35.22M

+25.8%

EBITDA

$37.24M

+18.7%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$206.32M

-37.2%

Accounts Receivable

$1.93M

-61.4%

Inventory

$0.00

N/A

Long Term Debt

$35.70M

-9.8%

Short Term Debt

$3.87M

+26.1%

Return on Assets

-47.43%

N/A

Return on Invested Capital

-60.54%

N/A

Free Cash Flow

$30.94M

+22.1%

Operating Cash Flow

$30.94M

+22.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

STROSutro Biopharma, Inc.

STROSutro Biopharma, Inc.$36.62+3.48%

ARTVArtiva Biotherapeutics, Inc.

ARTVArtiva Biotherapeutics, Inc.$10.24+17.43%

STTKShattuck Labs, Inc.

STTKShattuck Labs, Inc.$7.15+0.85%

MGNXMacroGenics, Inc.

MGNXMacroGenics, Inc.$3.08+4.76%

WHWKWhitehawk Therapeutics Inc

WHWKWhitehawk Therapeutics Inc$4.01-0.74%

IMMXImmix Biopharma, Inc.

IMMXImmix Biopharma, Inc.$8.93+3.48%

ALXOALX Oncology Holdings Inc.

ALXOALX Oncology Holdings Inc.$1.70+7.59%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$12.91+0.04%

AMZNAmazon

AMZNAmazon$265.06+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.10+0.04%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.63+0.10%

MARAMara Holdings

MARAMara Holdings$11.99+0.12%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.54+0.03%

FFord Motor Company

FFord Motor Company$12.08-0.01%

Questions About ZNTL

What is the current price of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals is trading at $3.98 per share.

What is the 52-week range for Zentalis Pharmaceuticals?

Over the past 52 weeks, Zentalis Pharmaceuticals has traded between $1.13 and $6.95.

How much debt does Zentalis Pharmaceuticals have?

As of the most recent reporting period, Zentalis Pharmaceuticals reported total debt of $39.58M.

How much cash does Zentalis Pharmaceuticals have on hand?

Zentalis Pharmaceuticals reported $35.99M in cash and cash equivalents in its most recent financial results.

What is Zentalis Pharmaceuticals’s dividend yield?

Zentalis Pharmaceuticals does not currently have a dividend yield.

Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Financials at a Glance

ZNTL News

Zentalis (ZNTL) Q2 Loss Narrows 70%

Why Shares of Zentalis Pharmaceuticals Dropped This Week

Is It Too Late to Jump In on Zentalis?

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Zentalis Pharmaceuticals

ZNTL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Zentalis Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ZNTL

What is the current price of Zentalis Pharmaceuticals?

What is the 52-week range for Zentalis Pharmaceuticals?

How much debt does Zentalis Pharmaceuticals have?

How much cash does Zentalis Pharmaceuticals have on hand?

What is Zentalis Pharmaceuticals’s dividend yield?

Premium Investing Services